Natera and Eledon Announce Strategic Partnership for Prospera™ Monitoring in Planned Phase 3 Kidney Transplant Trial
Eledon Pharmaceuticals partnered with Natera to exclusively use the Prospera dd-cfDNA test in its planned Phase 3 trial of tegoprubart for kidney transplantation. The trial is expected to enroll approximately 600 patients across over 100 transplant centers globally, with initiation slated for late 2026.
Key figures
- Phase Of Trial
- Phase 3
- Trial centers
- 100
- Trial enrollment target
- 600
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.